Pár A, Falus A
Acta Med Hung. 1986;43(4):343-9.
Serum beta 2-microglobulin (beta 2m) concentration is increased in pathological processes associated with lymphocyte activation. beta 2m and anti-beta 2m autoantibody (anti-beta 2m) determinations were made in the sera of 41 patients with chronic hepatitis and cirrhosis, respectively, in 19 with systemic lupus erythematosus (SLE) as well as in 27 healthy controls. A pathologically high beta 2m value was found in one-third of inactive persistent hepatitis, and in more than two-thirds of active hepatitis and postnecrotic cirrhosis cases. In SLE it occurred in 16 out of 19 cases. The beta 2m level was elevated mainly in HBV-negative and circulating immune complex-positive hepatic patients. Anti-beta 2m antibody occurred in one-third of chronic hepatitis, but only in one out of 13 cases in cirrhosis and in 12 out of nineteen patients with SLE. The results suggest that beta 2m and anti-beta 2m as in SLE may be further laboratory indicators of immunological activity in inflammatory hepatic disease.
血清β2-微球蛋白(β2m)浓度在与淋巴细胞活化相关的病理过程中会升高。分别对41例慢性肝炎和肝硬化患者、19例系统性红斑狼疮(SLE)患者以及27名健康对照者的血清进行了β2m和抗β2m自身抗体(抗β2m)检测。在三分之一的非活动性持续性肝炎患者中发现β2m值病理性升高,在三分之二以上的活动性肝炎和坏死后肝硬化病例中也有此现象。在SLE患者中,19例中有16例出现这种情况。β2m水平主要在乙肝病毒阴性且循环免疫复合物阳性的肝病患者中升高。抗β2m抗体出现在三分之一的慢性肝炎患者中,但在肝硬化患者的13例中仅有1例出现,在19例SLE患者中有12例出现。结果表明,如在SLE中一样,β2m和抗β2m可能是炎症性肝病免疫活性的进一步实验室指标。